JP5663699B2 - ピラゾール誘導体及びその医薬用途 - Google Patents

ピラゾール誘導体及びその医薬用途 Download PDF

Info

Publication number
JP5663699B2
JP5663699B2 JP2014514708A JP2014514708A JP5663699B2 JP 5663699 B2 JP5663699 B2 JP 5663699B2 JP 2014514708 A JP2014514708 A JP 2014514708A JP 2014514708 A JP2014514708 A JP 2014514708A JP 5663699 B2 JP5663699 B2 JP 5663699B2
Authority
JP
Japan
Prior art keywords
constipation
day
compound
administration
stool
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014514708A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013168671A1 (ja
Inventor
伊佐治　正幸
正幸 伊佐治
理明 竹村
理明 竹村
英俊 伊澤
英俊 伊澤
之彦 布袋
之彦 布袋
格 宮下
格 宮下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Priority to JP2014514708A priority Critical patent/JP5663699B2/ja
Application granted granted Critical
Publication of JP5663699B2 publication Critical patent/JP5663699B2/ja
Publication of JPWO2013168671A1 publication Critical patent/JPWO2013168671A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014514708A 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途 Active JP5663699B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014514708A JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
JP2012105847 2012-05-07
JP2014514708A JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途
PCT/JP2013/062755 WO2013168671A1 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014245645A Division JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
JP5663699B2 true JP5663699B2 (ja) 2015-02-04
JPWO2013168671A1 JPWO2013168671A1 (ja) 2016-01-07

Family

ID=49550709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014514708A Active JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途
JP2014245645A Active JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014245645A Active JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Country Status (15)

Country Link
US (2) US9273085B2 (enExample)
EP (1) EP2848254B1 (enExample)
JP (2) JP5663699B2 (enExample)
KR (1) KR101868991B1 (enExample)
CN (1) CN104284665B (enExample)
AU (1) AU2013258566B2 (enExample)
BR (1) BR112014027841B1 (enExample)
CA (1) CA2872002C (enExample)
DK (1) DK2848254T3 (enExample)
ES (1) ES2601127T3 (enExample)
MX (1) MX359988B (enExample)
PL (1) PL2848254T3 (enExample)
PT (1) PT2848254T (enExample)
RU (1) RU2602739C2 (enExample)
WO (1) WO2013168671A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
EP2848254B1 (en) * 2012-05-07 2016-08-03 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
WO2014119787A1 (ja) 2013-02-04 2014-08-07 大正製薬株式会社 便秘症の予防又は治療薬
CN106573033A (zh) * 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
US11596644B2 (en) 2018-03-28 2023-03-07 Avolynt Method for treating post-prandial hypoglycemia
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の１／２フマル酸塩

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP5291616B2 (ja) * 2006-04-26 2013-09-18 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
JPWO2011002001A1 (ja) * 2009-07-01 2012-12-13 キッセイ薬品工業株式会社 ピラゾール誘導体とビグアナイド薬との組み合わせ医薬
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
EP2848254B1 (en) * 2012-05-07 2016-08-03 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の１／２フマル酸塩

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014047874; Ｄｉａｂｅｔｅｓ　Ｊｏｕｒｎａｌ Ｖｏｌ．３１，　Ｎｏ．３, 2003, ｐ．８６-９１ *
JPN6014047875; モダンフィジシャン Ｖｏｌ．１８，　Ｎｏ．６, 1998, ｐ．７１７-７１９ *

Also Published As

Publication number Publication date
US9273085B2 (en) 2016-03-01
BR112014027841B1 (pt) 2022-08-09
RU2602739C2 (ru) 2016-11-20
CN104284665A (zh) 2015-01-14
PL2848254T3 (pl) 2017-03-31
PT2848254T (pt) 2016-10-05
EP2848254A1 (en) 2015-03-18
EP2848254B1 (en) 2016-08-03
AU2013258566B2 (en) 2017-03-16
CN104284665B (zh) 2016-11-16
BR112014027841A2 (pt) 2017-06-27
US20160129031A1 (en) 2016-05-12
JP6105546B2 (ja) 2017-03-29
WO2013168671A1 (ja) 2013-11-14
MX359988B (es) 2018-10-18
CA2872002C (en) 2019-01-15
CA2872002A1 (en) 2013-11-14
US20150141631A1 (en) 2015-05-21
KR101868991B1 (ko) 2018-06-19
BR112014027841A8 (pt) 2021-09-28
EP2848254A4 (en) 2015-07-15
KR20150013671A (ko) 2015-02-05
ES2601127T3 (es) 2017-02-14
US9694027B2 (en) 2017-07-04
JPWO2013168671A1 (ja) 2016-01-07
MX2014013696A (es) 2015-02-05
AU2013258566A1 (en) 2014-11-27
HK1204773A1 (en) 2015-12-04
RU2014149181A (ru) 2016-06-27
DK2848254T3 (en) 2016-10-31
JP2015083580A (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
JP6105546B2 (ja) ピラゾール誘導体及びその医薬用途
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
JP6448001B2 (ja) 液体配合剤
CN114929209A (zh) 肌萎缩侧索硬化的治疗
JP6473254B2 (ja) 下痢を治療するための製品及び方法
KR20240043778A (ko) 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
Marino et al. The Drug Update: Recent drug approvals
KR20200017487A (ko) 비알코올성 지방간염 치료를 위한 리코플리고진
TW202410887A (zh) 用於治療肌肉萎縮性脊髓側索硬化症之方法及組成物
JP6454436B1 (ja) ペマフィブラートを含有する医薬
CN106456620A (zh) 胃轻瘫用5‑ht4受体激动剂
TWI659739B (zh) 便秘症之預防或治療藥
CN116887822A (zh) 治疗软骨发育不全的方法
HK1204773B (en) Pyrazole derivative and use thereof for medical purposes
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
Hanson It’s Not the End: What’s New in Ileal Impactions
US20110269792A1 (en) Compositions useful for treating irritable bowel syndrome

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141208

R150 Certificate of patent or registration of utility model

Ref document number: 5663699

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250